logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Osteoporosis Steroidinduced

    FiltersReset Filters
    5 results

    • alendronate

      (ALENDRONATE SODIUM)
      Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.
      Usage: Alendronate sodium tablets are indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and treating Paget’s disease of bone. Use should be periodically re-evaluated, particularly for low-risk fracture patients after 3 to 5 years.

    • fosamax

      (alendronate sodium)
      Organon LLC
      Usage: FOSAMAX is indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and managing Paget's disease of bone. It enhances bone mass and reduces fracture incidence across these conditions. Regular reassessment for continued therapy is recommended.

    • prolia

      (denosumab)
      Amgen Inc
      Usage: Prolia is indicated for: treating osteoporosis in postmenopausal women and men at high fracture risk; glucocorticoid-induced osteoporosis; increasing bone mass in men undergoing androgen deprivation therapy for prostate cancer; and in women receiving aromatase inhibitor therapy for breast cancer. It reduces fracture incidence in these populations.

    • risedronate sodium

      (Risedronate Sodium)
      Greenstone LLC
      Usage: Risedronate Sodium is indicated for treating and preventing postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, and preventing glucocorticoid-induced osteoporosis. It also treats Paget’s disease of bone in both men and women. Optimal duration of therapy has not been established, warranting periodic re-evaluation.

    • risedronate sodium

      (Risedronate Sodium)
      Hangzhou Minsheng Binjiang Pharmaceutical CO., Ltd
      Usage: Risedronate sodium tablets are indicated for treating and preventing postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, preventing osteoporosis induced by glucocorticoids, and treating Paget's disease. Regular assessment for continued therapy is necessary due to undetermined optimal duration of use.